TFM
CRSP icon

TFC Financial Management’s CRISPR Therapeutics CRSP Stock Holding History

TFC Financial Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.8K Sell
620
-68
-10% -$3.58K ﹤0.01% 330
2026
Q1 		$32.7K Hold
688
– – ﹤0.01% 309
2025
Q4 		$36.1K Hold
688
– – ﹤0.01% 298
2025
Q3 		$44.6K Sell
688
-30
-4% -$1.72K 0.01% 278
2025
Q2 		$34.9K Hold
718
– – ﹤0.01% 291
2025
Q1 		$24.4K Buy
718
+40
+6% +$1.7K ﹤0.01% 307
2024
Q4 		$26.7K Sell
678
-80
-11% -$3.78K ﹤0.01% 291
2024
Q3 		$35.6K Buy
758
+58
+8% +$2.94K 0.01% 281
2024
Q2 		$37.8K Hold
700
– – 0.01% 255
2024
Q1 		$47.7K Hold
700
– – 0.01% 236
2023
Q4 		$43.8K Buy
700
+680
+3,400% +$37.6K 0.01% 237
2023
Q3 		$908 Hold
20
– – ﹤0.01% 537
2023
Q2 		$1.12K Hold
20
– – ﹤0.01% 503
2023
Q1 		$905 Hold
20
– – ﹤0.01% 517
2022
Q4 		$813 Hold
20
– – ﹤0.01% 480
2022
Q3 		$1K Hold
20
– – ﹤0.01% 456
2022
Q2 		$1K Hold
20
– – ﹤0.01% 448
2022
Q1 		$1K Sell
20
-269
-93% -$16.9K ﹤0.01% 468
2021
Q4 		$22K Hold
289
– – 0.01% 267
2021
Q3 		$32K Hold
289
– – 0.01% 232
2021
Q2 		$47K Hold
289
– – 0.02% 207
2021
Q1 		$35K Hold
289
– – 0.01% 213
2020
Q4 		$44K Buy
289
+20
+7% +$2.36K 0.02% 199
2020
Q3 		$22K Buy
+269
New +$23.9K 0.01% 229

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TFC Financial Management's CRSP Position: Q2 2026 in Review

TFC Financial Management reduced its CRISPR Therapeutics (CRSP) stake by 9.9% in Q2 2026, selling an estimated $3.58K and leaving 620 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #330.

TFC Financial Management first reported a position in CRSP in Q3 2020 and has held it in 24 quarters since. The position peaked at $47.7K in Q1 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • TFC Financial Management held 620 shares of CRISPR Therapeutics worth $33.8K as of Q2 2026.
  • TFC Financial Management sold 68 CRISPR Therapeutics shares in Q2 2026, an estimated $3.58K.
  • CRISPR Therapeutics made up ﹤0.01% of TFC Financial Management's portfolio in Q2 2026, its #330 holding.
  • TFC Financial Management first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • TFC Financial Management's CRISPR Therapeutics position peaked at $47.7K in Q1 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on TFC Financial Management's 13F filing for Q2 2026, filed 23 Jul 2026.